"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
Please provide your email address to receive an email when new articles are posted on . In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic ...
– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update. ImmuneOnco Biopharmaceuticals has announced the successful dosing of the first patient in its Phase III trial of ...
BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Merin, director of the leukemia program at Cedars-Sinai ...
(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback